Correlation Of Systemic Blood Pressure In Chronic Obstructive Pulmonary Disease With Serum Malondialdehyde Level

Abstract

Corresponding author's email: dharampbhadoria@yahoo.co.inRationale: Both chronic obstructive pulmonary disease (COPD) and hypertension have oxidative stress which contributes to the pathogenesis of inflammation. The malondialdehyde (MDA) has been demonstrated to be a potential biomarker of oxidative stress. Therefore, MDA could be an indicator of increased blood pressure (BP) in patients of COPD. This study was conducted to assess whether serum levels of MDA or putative antioxidants (superoxide dismutase, catalase and ascorbic acid) correlate with mean systemic BP (MBP) (an easy-to-measure surrogate marker for cardiovascular health) in COPD patients. Methods: This study includes eighty patients of COPD (GOLD stage II-IV) without diabetes mellitus, chronic liver or kidney disease, endocrinopathies or structural cardiac disease. Fifty age matched healthy individuals were included as controls. MDA was measured in the sera using the standard method described by Wright ., (1981). Serum levels of superoxide dismutase, catalase and ascorbic acid were et al measured by using standard protocols. The levels of MDA and antioxidants in COPD patients were compared with those obtained in sera of 50 healthy controls. BP was measured in sitting position on three occasions at one month intervals and the average MBP values were calculated. A total of 76 COPD patients successfully completed the study. Correlation study was performed by analysing all parametric data with relation to each-other and Pearson correlation coefficient (r) was calculated in each case. Further, regression analyses were done as appropriate, coefficient of determination (R ) values and graphs 2 obtained. Results: The mean±SD serum MDA levels in COPD and control groups were 0.66±0.37 μM/L and 0.50±0.43 μM/L, respectively. In COPD patients, there was a significant correlation of MBP with serum MDA levels (r=0.768, P=0.00001) (Figure 1). There was no correlation between BP, serum levels of antoxidants, age, smoking index, severity of airway obstruction or body mass index. Conclusion: Serum MDA level measurement can be used in patients of COPD with hypertension to assess systemic oxidative stress and to predict cardiovascular complications. Figure 1 Mean blood pressure (BP) (mmHg) vs serum malondialdehyde (MDA) (μM/L) COPD patients This abstract is funded by: